Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

BDX · Q2 2026 Earnings

Becton Dickinson

Reported May 7, 2026

30-second summary

SENTIMENT: Constructive Q2 revenue grew 5.2% YoY (+2.6% FXN) to $4.71B and adjusted EPS of $2.90 cleared the prior $2.72–$2.82 guide by $0.08 at the high end. Adjusted operating margin came in at 24.2% (-110 bps YoY), with 160 bps of tariff drag, ahead of management's internal expectations and consistent with the reaffirmed ~25% FY anchor. Management raised FY26 adjusted EPS to $12.52–$12.72 (midpoint up $0.12) while reaffirming low-single-digit revenue growth, ~25% adjusted operating margin, and the 16–17% tax rate. GAAP operating margin of 2.0% reflects $533M of integration/restructuring/transaction expense — including a $450M non-cash impairment tied to exiting activities that no longer align with the New BD strategy — and is not the relevant operating comparison.

Headline numbers

EPS

Q2 FY2026

$2.90

+4.7% vs est.

Revenue

Q2 FY2026

$4.71B

+5.2% YoY

+0.9% vs est.

Gross margin

Q2 FY2026

45.7%

Free cash flow

Q2 FY2026

$1.09B

Operating margin

Q2 FY2026

2.0%

Key financials

Q2 FY2026

Metric	Q2 FY2026	YoY	Q1 FY2026	QoQ
Revenue	$4.71B	+5.2%	$5.25B	-10.2%
EPS	$2.90	—	$2.91	-0.3%
Gross margin	45.7%	—	46.0%	-30bps
Operating margin	2.0%	—	10.5%	-850bps
Free cash flow	$1.09B	—	$0.55B	+99.5%

Guidance

Company raises full-year EPS guidance following Q2 beat while reaffirming revenue growth; several operational metrics (operating margin, tax rate, interest expense, shares) withdrawn from guidance.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Adjusted Diluted EPS	Q2 FY2026	$2.72 to $2.82	$2.90	+$0.08 to $0.18 above guide	Beat

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Adjusted Diluted EPS	FY 2026	$12.35 to $12.65	$12.52 to $12.72	+$0.17 to $0.37 at midpoint	Raised
Operating Margin	FY 2026	approximately 25%	Withdrawn — no replacement	—	Withdrawn
Interest Expense, net	FY 2026	$600 to $620 million	Withdrawn — no replacement	—	Withdrawn
Adjusted Effective Tax Rate	FY 2026	16% to 17%	Withdrawn — no replacement	—	Withdrawn
Weighted Average Shares Outstanding	FY 2026	approximately 282 million shares	Withdrawn — no replacement	—	Withdrawn

Reaffirmed unchanged this quarter: Revenue Growth (GAAP) (Low single-digit plus), Revenue Growth (FXN) (Low single-digit)

Segment KPIs

Q2 FY2026

Segment	Q2 FY2026	YoY
Medical Essentials	$1.647B	+4.7%
Connected Care	$1.12B	+4.9%
BioPharma Systems	$0.59B	+2.5%
Interventional	$1.357B	+7.3%

Other KPIs

Q2 FY2026

Segment	Q2 FY2026	YoY
United States	$2.917B	+5.1%
International	$1.797B	+5.5%
Revenue Growth (FXN)	2.6%	—
Adjusted Diluted EPS	$2.90	—
Operating Margin	2.0%	—
Gross Margin	45.7%	—
Accelerated Share Repurchase	$2.0 billion	—
Debt Retired	$2.1 billion	—

Management tone

Q3 FY25: executing through headwinds → Q4 FY25: defensive guidance reset → Q1 FY26: execution confidence with embedded drags → Q2 FY26: confidence reinforced by ahead-of-plan margins and explicit operating-margin reaffirmation.

Capital allocation has hardened from optionality to declared priority. Last quarter management announced the Waters $4B deployment ($2B ASR + $2B debt paydown) as a one-time mechanical event. This quarter management explicitly named buybacks as the top form of value creation and relegated M&A to "focused tuck-ins" at current valuation levels. The shift signals management believes the stock is materially undervalued and that buybacks are now the dominant near-term lever.

BD Excellence migrated from operations into R&D with quantified results. Three quarters ago BD Excellence was a manufacturing productivity program. Last quarter it expanded into R&D with anecdotal acceleration claims (six to twelve months). This quarter management put a number on it: "Year-to-date, we've applied BD Excellence to five development programs and, on average, have reduced the time to launch by over 10 months." The hardening from "anecdotal" to "averaged across a portfolio of programs" is the tonal upgrade, and BD Excellence delivered ~8% productivity in Q2.

Headwinds remain time-boxed transition mechanics. Alaris, vaccines and China collectively are <10% of revenue and tracking as expected. The Alaris headwind extends into FY27 with no longer a headwind in FY28; investors should not read the FY27 setup as "headwinds resolved."

A new operational item: the FDA warning letter on the El Paso ChloroPrep / PurePrep facility triggered a voluntary ~3-week U.S. shipment hold pending additional final release testing (the same testing already performed for European product). Manufacturing continues; no patient safety signals.

Recurring themes management leaned on this quarter:

Portfolio quality and breadth: 90% of portfolio growing mid-single-digit; multiple platforms in double-digit growthBD Excellence scaling across operations, commercial, and R&D; 8% productivity in Q2 with 2,000+ Kaizans executed annuallyHeadwind monetization: Clear quantification and timeline for Alaris, vaccine, and China pressures to resolve by FY28Margin expansion via BD Excellence and mix shift to higher-growth, higher-margin platformsCapital allocation reframed: Share buybacks now priority at current valuation; disciplined M&A deferredInnovation velocity accelerating: 10-month average timeline reduction in R&D projects; increased launch cadence in high-growth categories

Risks management surfaced:

Alaris will carry 200 basis point headwind into FY27 before stabilizingVaccine market demand decline; uncertainty on whether repeat decline will occur in FY27China market dynamics expected to persist; VBP pressure to continue; China revenue declining to ~3% of totalTariff impact of 160 basis points on gross margin; oil and resin price inflation (5% of COGS) mitigated by hedges with time limitationsFDA warning letter on El Paso ChloroPrep/PurePrep facility; 3-week testing hold on U.S. shipments (though European product already tested)

Answers to last quarter's watch list

Q2 adjusted EPS vs. $2.72–$2.82 guide — Q2 adjusted EPS of $2.90 cleared the high end by $0.08. Status: Resolved positively

FY26 EPS bridge clarity for New BD — management raised FY EPS by $0.12 at midpoint and reaffirmed the ~25% adjusted operating margin and 16–17% tax rate. The "operationally unchanged" framing is intact. Status: Resolved positively

Operating margin progression toward the FY ~25% guide — Q2 adjusted operating margin of 24.2% (-110 bps YoY, 160 bps tariff drag) is ahead of management's internal plan and consistent with the reaffirmed FY ~25% anchor. Status: Resolved positively

Commercial excellence revenue uplift — Interventional +5.3% FXN and APM +12% suggest commercial discipline is translating; the Pyxis Pro early launch with 75% competitive-conversion mix is supportive. Status: Continue monitoring

Tax rate at 16–17% holding — reaffirmed. Status: Resolved positively

$2B ASR pace and debt paydown execution — $2.0B ASR completed and $2.1B debt retired in the quarter, in line with the "near-term" commitment. Status: Resolved positively

What to watch into next quarter

Q3 adjusted EPS cadence — with H1 EPS of $5.38 and FY midpoint of $12.62, H2 implies ~$7.24. Watch whether Q3 lands at or above ~$3.50 to keep a balanced H2 shape vs. a Q4-loaded cadence that would re-introduce back-half-heroics risk.

El Paso ChloroPrep remediation timing — the 3-week U.S. shipment hold is qualified as "subject to successful testing." Any delay or expansion would hit Medical Essentials and Surgery (where ChloroPrep mostly sits) in Q3.

Adjusted operating margin trajectory to ~25% — Q2 at 24.2% implies H2 needs to step up to land the FY at ~25%. BD Excellence productivity (8% run rate) and tariff cap-and-roll are the main levers.

BioPharma Systems vaccine lap — vaccine drag started late Q2 FY25; H2 comps ease. Watch whether biologics double-digit growth (now ~55% of segment) lifts reported segment growth.

Capital deployment cadence post-ASR — management named buybacks as top priority "at current valuation levels." Watch for incremental authorization or open-market activity beyond the completed $2B ASR.

Alaris competitive funnel conversion — management cited the largest competitive funnel in company history; conversion pace will determine whether share gains accelerate beyond the current ~150 bps YTD.

Sources

BDX Q2 FY2026 press release (filed 2026-05-07): https://www.sec.gov/Archives/edgar/data/10795/000162828026031638/ex9913312026.htm
BDX Q2 FY2026 earnings call transcript (2026-05-07).

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.